| Home and Order Page | 

Uprima

The Most Powerful HGH Stimulant Available
and one of the quickest and most reliable ED drugs available.  Order now from a most reputable USA Compounding Pharmacy!

Apomorphine  is not morphine, is not a narcotic and is non-addictive. It will probably not be patented in the USA since it already exists as a Generic drug that can be prescribed by any doctor for any purpose. In Europe it is a best selling ED drug (Probably the best) and in the USA it is an "Investigational Drug", is used for many reasons including  Parkinson's Disease. 3mg sublingual tablets, just like you would buy in Europe, can be purchased from and Compounded by a qualified "Compounding Pharmacist" such as Stark Professional Pharmacy in Overland Park, Kansas.  To read more on this subject or on any other abstract below just click on the "Related Articles" link at each Abstract and it will take you to The National Institute of Health Data Base. This way you can do your own research.

You will need a prescription from your doctor and to help you with this we have made available to you the "Package Leaflet" from a box of Uprima which is Apomorphine Hydrochloride from Europe. You might want to also give your doctor the web page called "Uprima".

We also have an order page that tells you what to ask your Doctor for and how to send it to Stark Professional Pharmacy in Overland Park, Kansas.  This Order Form must be mailed in by you or telephoned in by your doctor at toll free  877-473-6663 ! You should receive your prescription in 5-7 days.  You mail the prescription to:

Stark Pharmacy
Menorah Medical Center
119th & Nall - 5701 W. 119th
Overland Park, Kansas  66209-3721

Ask your Doctor for multiple re-fills.

There is a great deal that remains unknown about growth hormone. For example, scientists still do not fully understand how it works. They do know that growth hormone triggers the production by the liver of another hormone called "insulinlike growth factor," or "IGF-1." Most likely the effects of growth hormone are actually  due to the action of IGF-1. DHEA also increases the production of IGF-I, so  DHEA's strengthening effect on the immune system may relate to its  ability to promote the production of IGF-1. This shows, yet again, how hormones work in conjunction with each other to produce the fantastic symphony we know as "LIfe".

As we age it has been found  that elderly men,(and probably women: Editors note) have a decreased reserve of hypothalamic GHRH (growth Hormone Releasing Hormone), resulting in secondarily impaired Growth Hormone (GH) release, which may lead to a lower level of IGF-I than in young people.(3)

Just  as testosterone, DHEA, Pregnenolone and other hormone  levels drop with age, so too does HGH and therein lies the potential importance of growth hormone release induced by apomorphine (1)

Apomorphine increased serum GH levels above 10 ng/ml in all subjects 30-60 min after administration.(2)

Apomorphine appears to work on both men & women, which is good news for women. There was no statistical difference between men and women in whom apomorphine testing was utilized.(4)

For the Editor, apomorphine taken sublingually (between cheek and gum) in 1.5mg nightly bedtime doses has meant a higher core body temperature associated with better sleep, much higher IGF-1 levels which means a powerful immune system and fast healing & a general zest for life and all activities.  The maintenance of muscle mass and bone density appears constant and seems to work well with testosterone replacement therapy.

For more information on any of the annotated subjects just click on the  "Related Articles" link associated with each reference cited.

Psychiatry Res 1988 Mar;23(3):245-55     Related Articles,

(1.)Sensitization and tolerance to apomorphine in men: yawning, growth hormone, nausea, and hyperthermia.

Szechtman H, Cleghorn JM, Brown GM, Kaplan RD, Franco S, Rosenthal K.
Ontario Mental Health Foundation, Canada.

This study investigated whether the indices of dopaminergic function, yawning and growth hormone release induced by apomorphine, as well as the drug-induced nausea and hyperthermia (High Temperature), show sensitization or tolerance to repeated injections. Five normal volunteers received 12 injections of apomorphine hydrochloride (0.75 mg/70 kg) every 2 weeks. Yawning, as measured by the latency of onset and the time of peak activity, showed sensitization. The growth hormone response showed no change (In other words it kept on working). Feelings of nausea and hyperthermia showed tolerance (reduced long term effectiveness) to repeated injections. These findings suggest that yawning may be a suitable index of dopaminergic function in studies of schizophrenia.

PMID: 3387500 [PubMed - indexed for MEDLINE]

| Back |

Clin Endocrinol (Oxf) 1975 May;4(3):277-85      Related Articles


(2.)Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men.

Lal S, Martin JB, De la Vega CE, Friesen HG.

Apomorphine hydrochloride (0.75 mg s.c.[Under the skin]) has been compared with L-dopa (500 mg p.o.) in their effects on growth hormone secretion in a double blind cross-over study involving nine healthy men. Apomorphine increased serum GH levels above 10 ng/ml in all nine subjects 30-60 min after injection. In contrast, only six of these subjects showed a similar elevation with L-DOPA and in only three had the level increased above 6 ng/ml by 60 min. One subject failed to respond to L-dopa and in two others the peak was less than 6 ng/ml. GH levels were significantly higher at 30, 45 and 60 min following apomorphine than following L-dopa. Apomorphine-induced GH release was not related to changes in serum cortisol or blood sugar. Benztropine mesylate (1 mg i.m.) had no effect on apomorphine-induced GH release. These results suggest: (a) apomorphine may have advantages over L-dopa as a provocative agent to assess GH secretory capacity; (b) a dopaminergic mechanism subserves GH secretion; (c) cholinergic mechanisms do not antagonize dopaminergic-related GH release.

Publication Types:
Clinical Trial
Controlled Clinical Trial

PMID: 1149303 [PubMed - indexed for MEDLINE]

| Back |

 
Acta Endocrinol (Copenh) 1991 Jan;124(1):31- Related Articles    

(3.)Impaired secretion of growth hormone-releasing hormone, growth hormone and IGF-I in elderly men.

Bando H, Zhang C, Takada Y, Yamasaki R, Saito S.

First Department of Internal Medicine, School of Medicine, University of Tokushima, Japan.

The GHRH test and L-dopa test were performed in 12 normal young men (24.1 +/- 1.1 years) and 12 normal elderly men (77.8 +/- 1.4 years) to investigate age-related changes in secretion of GHRH, GH and IGF-I. The basal plasma levels of GHRH and GH were not significantly different in young and elderly men, but the basal plasma level of IGF-I was higher in the young men (159.0 +/- 11.7 vs 86.7 +/- 11.6 micrograms/l). The area under the curve for plasma GH in the GHRH test was less in the elderly group (35.1 +/- 5.9 vs 11.2 +/- 2.1 micrograms.h-1.l-1, p less than 0.001). The AUCs for the plasma GHRH and GH responses in the L-dopa test in young and elderly men were 32.0 +/- 2.7 vs 20.3 +/- 1.8 ng.h-1.l-1 (p less than 0.001), and 21.8 +/- 4.6 vs 5.4 +/- 1.1 micrograms.h-1.l-1 (p less than 0.01), respectively, indicating decreased releases of GHRH and GH in the elderly. Correlations between the AUCs for plasma GHRH and GH responses in L-dopa were found in both groups, but the ratio of the AUCs for GH/GHRH was lower in the elderly group. The elderly group showed a significant correlation between the basal plasma IGF-I level and the AUCs for plasma GH in the GHRH and L-dopa tests. These results suggest that elderly men have a decreased reserve of hypothalamic GHRH, resulting in secondarily impaired GH release, which may lead to a lower level of IGF-I than in young men.

PMID: 2000699 [PubMed - indexed for MEDLINE]

| Back |

 
Am J Med. 1977 Dec;63(6):909-13. Related Articles,  

(4.)Apomorphine-stimulated growth hormone release.

La Rossa JT, Agrin R, Melby JC.

Apomorphine, a dopaminergic receptor stimulant, was tested and compared in subemetic (Lower amounts than that needed to induce vomiting) doses (0.76 mg subcutaneously) to levodopa (500 mg orally) as a stimulant of growth hormone release in 10 normal volunteer subjects (five male, five female). The administration of levodopa failed to cause a normal increment in serum growth hormone levels (greater than 5 ng/ml from base line) in four patients, produced a borderline normal response in two patients with a normal response in four patients. Apomorphine stimulation produced a borderline normal response in one patient and a normal response in the remaining nine patients. The peak response to apomorphine administration was 26.94 +/- 6.60 ng/ml and to levodopa 9.76 +/- 2.67 ng/ml (p less than 0.025). There was no statistical difference between men and women in whom apomorphine testing was utilized. Side effects (nausea, vomiting) were seen in three patients tested with levodopa and in four patients tested with apomorphine. Such symptoms began within 20 minutes of apomorphine administration, persisted from 30 to 40 minutes and disappeared abruptly. All patients treated with apomorphine noted transient drowsiness.
 

| Back |